Canadian Center for Vaccinology (DepoVax Study: Participants needed for research study at the IWK/Canadian Center for Vaccinology)

Organization Name: Canadian Center for Vaccinology
Opportunity Title: DepoVax Study: Participants needed for research study at the IWK/Canadian Center for Vaccinology
Category: Research
Commitment: Ongoing Opportunity (> 1 year)
Start Date: May 26, 2015
End Date: December 31, 2015

Email: ccfv@iwk.nshealth.ca
Website: http://www.vaccineresearch.ca
Details:

• Appropriate for volunteers aged between 18 and 55
• Appropriate for volunteers aged 55 and over

Opportunity Description:

Participants needed: Healthy Adults, aged 50-64. Participants will be compensated for their time and for out-of-pocket expenses such as parking at the IWK Health Centre. This includes $50 for the vaccination visit and $25 for other visits. Participants will also be provided with an electronic tablet to use as a diary/memory aid during the course of the study, which they may choose to keep following study close. Respiratory Syncytial Virus (RSV) is the most common cause of severe respiratory illness in infants and children; it is the reason why most children under the age of two in North America are admitted to the hospital. Every year, outbreaks of RSV occur between December and May. Almost all infants and young children are infected with RSV by the age of two years. In infants, RSV causes breathing problems such as wheezing and rapid breathing. RSV also infects people over 65 years of age. It can be especially serious in people who are frail or have weak immune systems. In this age group, people may have influenza-like symptoms such as fever, cough, and generally feeling unwell or worsening of heart or lung diseases, requiring admission to hospital for supportive care. The use of adjuvants (immune boosters) in the vaccine might be one way to improve the protectiveness of a vaccine against RSV. This study will assess the safety and protectiveness of a new adjuvant when added to an RSV antigen (dead germ) and given by injection to healthy adults. This is the first time this vaccine has been tested in humans. The purpose of the study is to: Assess the safety of the RSV vaccine Evaluate how well tolerated a single dose of a new RSV antigen combined with DepoVax adjuvant is by healthy participants aged 50 to 64 years, and how well tolerated a booster dose is Learn how much immune response can be measured at different times after receiving the injection. The Canadian Center for Vaccinology is the Sponsor of the study; that means the researchers at the Center designed and are leading this study. The vaccine is provided by a company called Immunovaccine, the developer of the vaccine that is being tested. Participation in the study will include 7 visits to the IWK Health Centre in Halifax. The total time commitment is 5–10 hours over a 9-month period. Contact Pamela MacIntyre Phone 902-470-8948